Laura Minarsch

Laura Minarsch is a senior executive in the medical device industry with 30+ years of experience in clinical development and trial strategy, including the design, development, and execution of first-in-human (FIH) studies. Laura joined ICS at its inception in 2013 and has been instrumental in defining key scientific relationships with opinion leaders and investigators contributing to the ongoing needs of the neuro embolic protection space. Throughout her career, Laura has facilitated numerous clinical studies in interventional cardiology and structural heart spaces – evaluating devices for PCI, TAVR, TMVR, and heart failure. Laura’s efforts contributed to the acquisitions of Embolic Protection, Inc. (acquired by Boston Scientific), Lazarus Effect (acquired by Covidien), Maya Medical (acquired by Covidien), Apama Medical (acquired by Boston Scientific), and Securus Medical (acquired by Boston Scientific). Laura is a registered cardiovascular invasive specialist RCIS, RT (R), and certified clinical research professional CCRP. She holds an A.S. in Radiologic Technology from Fullerton College and a B.S. from the University of Redlands. Laura is on the editorial board of Cath Lab Digest and has co-authored numerous scientific publications.